---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-006739"
form_type: "8-K"
ticker: "MXCT"
cik: "0001287098"
company_name: "MAXCYTE, INC."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T07:14:59.308068+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# MaxCyte Q1 2025 revenue down 8% to $10.4M; reiterates FY2025 guidance

## Summary
- Total revenue $10.4M (-8% YoY); core revenue $8.2M (+1%); SPL program revenue $2.1M (-32%).
- Net loss $10.3M vs $9.5M in Q1 2024; cash $174.7M as of March 31, 2025.
- Added one SPL client (TG Therapeutics); total active SPLs now 29.
- Reiterates FY2025: core revenue growth 8-15%, SPL program revenue ~$5M, ending cash ~$160M.
- Integration of SeQure Dx ongoing; management cites robust SPL pipeline.

## SEC filing metadata
- accession: 0001558370-25-006739
- form_type: 8-K
- ticker: MXCT
- cik: 0001287098
- company_name: MAXCYTE, INC.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1287098/000155837025006739/0001558370-25-006739-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1287098/000155837025006739/mxct-20250507x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-006739
- JSON: https://secwatch.observer/filing/0001558370-25-006739.json
- Plain text: https://secwatch.observer/filing/0001558370-25-006739.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.